重庆博腾制药科技股份有限公司独立董事 关于第五届董事会第十八次会议审议相关事项的 独立意见 根据《中华人民共和国公司法》、《关于在上市公司建立独立董事制度的指导意 见》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监管 指引第 2 号—创业板上市公司规范运作》等法律、法规和规范性文件，以及《重庆 博腾制药科技股份有限公司章程》（以下简称"《公司章程》"）和《重庆博腾制 药科技股份有限公司独立董事工作制度》等相关规定，作为重庆博腾制药科技股份 有限公司（以下简称"公司"）独立董事，基于独立判断的立场，现对公司第五届 董事会第十八次会议审议相关事项发表独立意见如下： 一、关于 2023 年上半年公司控股股东及其他关联方占用公司资金、公司对 外担保情况的专项说明和独立意见 经核查，我们认为： 1、2023 年上半年，公司不存在控股股东及其他关联方占用公司资金的情况； 2、2023 年上半年，公司对外担保情况： 截至 2023 年 6 月 30 日，公司对外担保余额为人民币 33,981.73 万元，占公司 2022 年末经审计净资产的 5.25%，具体如下： 1、公司第四届董事会第四十二次会议 ...

股票代码：300363 股票简称：博腾股份 公告编号：2023-061 号 重庆博腾制药科技股份有限公司 关于 2020 年限制性股票激励计划预留授予的第三个 解除限售期解除限售条件成就的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 5、2020 年 8 月 10 日，公司召开第四届董事会第十九次会议、第四届监事 会第十四次会议，审议通过《关于向激励对象授予 2020 年限制性股票激励计划 预留限制性股票的议案》。公司独立董事对上述议案发表了表示同意的独立意见， 认为预留授予条件已经成就，预留授予激励对象主体资格合法有效，确定的预留 授予日符合相关规定。监事会对预留授予激励对象名单进行核查并发表了核查意 见。 1、本次解锁的限制性股票数量为 1.68万股，占公司总股本的比例为 0.003%； 实际可上市流通的股票数量为 0 万股，占公司总股本的比例为 0.000%。 2、本次限制性股票办理完解锁手续后、上市流通前，公司将发布相关提示 性公告，敬请投资者注意。 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日召 ...

关于重庆博腾制药科技股份有限公司 北京市万商天勤律师事务所 2020 年限制性股票激励计划预留授予的 第三个解除限售期解除限售条件成就及 回购注销部分限制性股票相关事宜之 法律意见书 1 北京市万商天勤律师事务所 关于重庆博腾制药科技股份有限公司 2020 年限制性股票激励计划预留授予的第三个解除限售期解除限售 条件成就及回购注销部分限制性股票相关事宜之 法律意见书 致: 重庆博腾制药科技股份有限公司 北京市万商天勤律师事务所（下称"本所"或"万商天勤"）接受重庆博腾制药科技股 份有限公司（下称"博腾股份"或"公司"）的委托，就关于《2020 年限制性股票激励计 划（草案）》（以下简称"《2020 年激励计划》"）及《2021 年限制性股票激励计划（草案）》 （以下简称"《2021 年激励计划》"）相关事宜出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国 证券法》（以下简称"《证券法》"）、中国证券监督管理委员会（以下简称"中国证监会"） 《上市公司股权激励管理办法》（以下简称"《管理办法》"）等法律、法规和规范性文件的 规定，按照律师行业公认的业务标准、道 ...

股票代码：300363 股票简称：博腾股份 公告编号：2023-063 号 重庆博腾制药科技股份有限公司 第五届监事会第十四次会议决议公告 公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）第五届监事会第十四 次会议于 2023 年 8 月 17 日（星期四）以现场会议方式召开，会议通知已于 2023 年 8 月 7 日通过电子邮件方式送达各位监事。本次会议应参与表决监事人数 3 人，实际参与表决监事人数 3 人。本次会议由监事会主席谭永庆先生主持。 会议在保证所有监事充分发表意见的前提下，以投票的方式进行表决。会议 召开符合《公司法》及《公司章程》的规定，所作决议合法有效。 一、 会议审议情况 经与会监事认真审议，以投票表决方式通过以下议案： 1、审议通过《关于 2023 年半年度报告全文及其摘要的议案》； 表决结果： 3 票同意， 0 票反对， 0 票弃权 4、审议通过《关于回购注销部分限制性股票的议案》。 具体内容请见公司同日于巨潮资讯网（www.cninfo.com.cn）发布的《2023 年 半年度报告》和 ...

股票代码：300363 股票简称：博腾股份 公告编号：2023-062 号 重庆博腾制药科技股份有限公司 关于回购注销部分限制性股票的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日召开第五届董事会第十八次会议、第五届监事会第十四次会议，审议通过《关 于回购注销部分限制性股票的议案》，根据《2020 年限制性股票激励计划（草 案）》（以下简称"2020 年股权激励计划"）、《2021 年限制性股票激励计划 （草案）》（以下简称"2021 年股权激励计划"）关于限制性股票回购注销的 相关规定，鉴于 4 名激励对象已离职，不再具备激励对象资格，公司将对该 4 名离职激励对象已获授但尚未解锁的限制性股票 6.66 万股进行回购注销。具体 情况如下： 一、回购注销限制性股票情况 （一）激励计划概述 1、2020 年股权激励计划 （1）2020 年 6 月 5 日，公司召开第四届董事会第十六次临时会议，审议通 过《关于公司<2020 年限制性股票激励计划（草案）>及其摘要的议案》、《关 ...

股票代码：300363 股票简称：博腾股份 公告编号：2023-060号 重庆博腾制药科技股份有限公司 关于增聘高级管理人员的公告 截至本公告披露日，马雄斌先生未直接及间接持有公司任何股份，未在其他 单位或者公司兼职，与持有公司 5%以上股份的股东、实际控制人及公司其他董 事、监事、高级管理人员不存在关联关系，未受过中国证监会及其他有关部门的 处罚和证券交易所惩戒，不存在《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》第 3.2.3 条所规定的情形，也不属于失信被执行 人，符合《公司法》等相关法律、法规和规定要求的任职条件。 黄渊明，男，中国国籍，出生于 1979 年 8 月，硕士。曾就职于华为技术有 限公司、顺丰控股有限公司、天音通信控股股份有限公司、盈佳信联科技集团有 限公司、上海云砺信息科技有限公司等企业，拥有 20 年人力资源管理经验。现 任公司副总经理，负责公司人力资源管理工作。 重庆博腾制药科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日 召开第五届董事会第十八次会议，审议通过《关于增聘高级管理人员的议案》， 结合公司经营发展需要，同意增聘马雄斌先生、 ...

Financial Performance - The company's revenue for Q1 2023 was ¥1,377,802,786.78, a decrease of 4.50% compared to ¥1,442,770,395.49 in the same period last year[3] - Net profit attributable to shareholders was ¥304,092,146.15, down 20.37% from ¥381,898,709.67 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥296,262,380.67, reflecting a decline of 22.24% compared to ¥381,009,392.25 in the previous year[3] - Basic and diluted earnings per share were both ¥0.56, down 20.00% from ¥0.70 in the previous year[3] - In Q1 2023, the company achieved total revenue of 1.378 billion yuan, a year-on-year decrease of approximately 5% due to the delivery of significant orders received in previous periods[16] - The net profit attributable to shareholders was 358 million yuan, down about 14% year-on-year, primarily due to losses from emerging businesses[16] Cash Flow and Operating Activities - The company's cash flow from operating activities increased by 8.68% to ¥363,297,371.75 from ¥334,267,821.88 in the same period last year[3] - In Q1 2023, the company received cash related to operating activities amounting to ¥167,052,654.12, a significant increase of 539.25% compared to ¥26,132,511.55 in Q1 2022, primarily due to an increase in the recovery of deposit guarantees[9] - The cash paid for purchasing goods and services was ¥803,815,554.48, reflecting a 49.24% increase from ¥538,622,704.50 in the same period last year, attributed to higher procurement payments[9] - Cash paid for other operating activities decreased by 40.26% to ¥77,319,398.81 from ¥129,436,828.59, mainly due to a reduction in deposit guarantees paid[9] - Total cash inflow from operating activities reached CNY 1,698,129,800.41, compared to CNY 1,395,007,604.29 in the same period last year, indicating a year-over-year increase of about 21.7%[30] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥10,023,735,617.15, a decrease of 1.19% from ¥10,144,292,774.55 at the end of the previous year[3] - Total liabilities decreased to CNY 3,240,995,132.55 from CNY 3,672,000,486.45, a reduction of 11.7%[25] - Non-current liabilities increased to CNY 911,552,118.09 from CNY 656,007,317.81, an increase of 38.8%[25] - The company's total equity rose to CNY 6,782,740,484.60, up from CNY 6,472,292,288.10, indicating a growth of 4.8%[25] Research and Development - Research and development expenses rose by 58.20% to ¥165,970,275.02, driven by an increase in R&D personnel and ongoing investments in technology platforms[8] - Research and development expenses increased to CNY 165,970,275.02, up 58% from CNY 104,914,096.80 in Q1 2022[26] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 62,971[11] - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 14.46% of the shares, totaling 78,982,719 shares[11] Strategic Investments - The company’s strategic investments included the acquisition of 100% equity in Kaihui Pharmaceutical (Shanghai) Co., Ltd[16] Employee and Operational Metrics - The company’s employee count rose to 5,377, a 29% increase compared to the same period last year[16] - The company reported a total of 299 signed customer orders, representing a year-on-year growth of approximately 30%[16] - The number of single customers increased to 37, marking a year-on-year growth of 68%[16] Tax and Government Subsidies - The company received government subsidies amounting to ¥10,058,624.94, an increase of 263.12% compared to ¥2,770,023.02 in the previous year[8] - The company reported a significant increase in tax expenses, with a decrease in profit leading to a tax expense of ¥38,052,887.60, down 36.02% from ¥59,477,591.43 in the previous year[8] - The company received CNY 79,897,199.77 in tax refunds, compared to CNY 98,430,190.82 in the previous year, reflecting a decrease of approximately 18.5%[30] Cash and Financing Activities - Cash received from borrowings was ¥159,806,540.09, a decrease of 71.42% compared to ¥559,126,133.95, primarily due to reduced bank borrowings[9] - Cash paid for debt repayment was ¥127,298,000.00, down 59.50% from ¥314,350,305.64, reflecting a decrease in bank loan repayments[9] - The company distributed dividends and interest payments totaling ¥5,086,369.72, a decrease of 67.49% from ¥15,644,093.33, attributed to lower interest payments[9] - The net cash flow from financing activities was CNY 32,743,083.39, down from CNY 255,142,167.21 in Q1 2022, indicating a decrease of approximately 87.2%[30] Audit Information - The company did not conduct an audit for the Q1 2023 report[31]

Group 1: Strategic Focus Areas - The company's strategic focus for 2023 revolves around five key areas: "end-to-end" capabilities, globalization, new business development, digitalization, and breakthroughs in new technologies [1][2]. - The emphasis on "end-to-end" capabilities aims to enhance early-stage services in the CDMO sector [1]. - Globalization is viewed as both a challenge and an opportunity, prompting organizational and business transformations [2]. Group 2: Financial Performance and Projections - In 2022, the company experienced significant increases in gross margin and net profit margin due to high capacity utilization and cost-reduction R&D efforts [2][3]. - For 2023, a decline in gross and net profit margins is anticipated due to the completion of large orders and ongoing investments in new business ventures [2][3]. Group 3: Expense Management - The increase in expenses in 2022 was attributed to higher management, sales, and R&D costs, driven by organizational expansion and ongoing technology development [3]. - The company expects overall expenses in 2023 to remain stable compared to 2022, although the expense ratio may rise [3]. Group 4: Shareholder Returns - The company announced a cash dividend payout ratio of 30% for 2022, totaling CNY 602 million, alongside a share buyback amounting to CNY 1 billion, reflecting a commitment to shareholder returns [5]. Group 5: Risk Management and Challenges - The company faces macroeconomic challenges, including geopolitical influences, a difficult financing environment, and the need for technological advancements [6]. - Emphasis is placed on enhancing internal controls and compliance to mitigate risks associated with international operations [4][6].